Background: Multi-phenotype genome-wide association studies (MP-GWAS) of correlated traits have greater power to detect genotype-phenotype associations than single-trait GWAS. However, no multiphenotype analysis method exists for epigenome-wide association studies (EWAS).
Background
Multi-phenotype genome-wide association studies (MP-GWAS) of correlated traits are more powerful,
give better precision of estimates, and provide enhanced biological insight, i.e. suggestion of potential pleiotropic effects, as compared to single-phenotype GWAS [1] [2] [3] [4] [5] [6] . We have previously developed an MP-GWAS method using the "reverse regression" approach in which allele dosage is regressed on a linear combination of phenotypes, implemented into the software tool SCOPA and meta-analysis tool METASCOPA 7 . However, no multi-phenotype epigenome-wide association study (MP-EWAS) method exists, although EWAS have recently gained increased attention due to advances in technology and thus lowered costs of measuring epigenetic regulation.
DNA methylation is a type of epigenetic regulation and is most widely used within EWAS. Methylation refers to the attachment of methylation groups to the DNA molecule. Methylation of CpG islands within a gene's promoter usually implies that that the gene is not transcribed. DNA methylation is tissue-specific, reversible, and inheritable. Usually, the cytosine copies on both strands are either methylated or unmethylated.
In correlated traits, there is a considerable, although incomplete, overlap between the measures of glucose homeostasis and type 2 diabetes (T2D). For instance, the genetic correlation between fasting glucose levels (FG) and fasting insulin levels (FI) estimated by cross-trait LD Score regression is 0.31, and the genetic correlations between FG and T2D and between FI and T2D are 0.58 and 0.48, respectively 8 .
The study of glycaemic traits in healthy individuals can provide insights about the pathophysiology of T2D, and the (epi)genetic study on these phenotypes can inform on the molecular mechanisms leading to T2D -also those influenced by individual's lifestyle and environmental exposures, as they have been shown to leave a mark on the individual's epigenome 9 . One of the advantages of studying glycaemic traits, rather than T2D, is that sample sizes can be much larger, as they are independent of T2D prevalence. Indeed, genome-wide methylation in blood has been associated with body mass index, T2D and measures of glucose metabolism [10] [11] [12] . However, no study has previously aimed at unravelling the epigenetics of these traits by taking into account their correlations with each other, most likely due to the lack of appropriate methodology.
Our aims in the current work were two-fold. First, we aimed to extend the reverse regression approach for methylation data and implement it in a software tool. We addressed this aim by developing methylSCOPA (Software for COrrelated Phenotype Analysis with methylation data), which is the SCOPA extension for DNA methylation data. methylSCOPA association summary statistics can also be aggregated across EWAS through fixed-effects meta-analysis, implemented in META-methylSCOPA, which is the META-SCOPA extension for MP-EWAS meta-analysis. Analogous to META-SCOPA, this enables application of reverse regression in large-scale international consortia efforts where, for instance, ethical concerns and legal restrictions preclude joint analysis of individual-level genome-wide DNA methylation and phenotype data from different studies. Second, we aimed to test the method for epigenetic effects on FG & FI variability. We report one novel methylation probe associated with FG and FI from these analyses and dissect the multi-phenotype epigenetic effects at 11 established methylation marks for metabolic traits.
Implementation
Reverse regression model of multiple correlated phenotypes methylSCOPA extends the SCOPA analysis framework 7 to the analysis of DNA methylation data.
Specifically, this means that methylSCOPA allows for methylation (instead of genotype as in SCOPA) data as input, and that it analyses methylation data analogous to the way in which SCOPA analyses genotype dosage data.
DNA methylation assays in tissue samples return at any given site an average methylation percentage for a mixture of cells. These percent methylation values are continuous and range from 0 to 100 13 . In methylSCOPA we model these percent methylation values as a function of the observed phenotypes using linear reverse regression, analogous to how SCOPA models the genotype at a single-nucleotide polymorphism (SNP) as a function of the observed phenotypes. Therefore, analogous to expression (1) For further dissection of epigenome-wide significant (p<110 -7 ) multiple-phenotype association signals, the analysis of different phenotype combinations is enabled. We assess the model fit within each phenotype combination through the use of the Bayesian Information Criterion (BIC), with the smallest value indicating the best fit.
Meta-analysis of multiple EWAS of the same set of correlated phenotypes is enabled through the application of the method for the synthesis of regression slopes 14 , similarly to METASCOPA 7 . We further implemented model selection for the signals reaching epigenome-wide significance in the meta-analysis by using the 'meta-Bayesian Information Criterion' (meta-BIC) value. Following the notation from Bohning 15 , the likelihood is defined as
and the meta-likelihood as
The value of the Bayesian Information Criterion is calculated as in Wit et al. 16 
= ln( ) − 2 ln(̂)
where ̂= maximized value of likelihood function = (combined) sample size = number of parameters estimated by the model Therefore, the value of the meta-log-likelihood can simply be computed as the sum of the log-likelihoods of the individual studies, and the 'meta-BIC' value for the meta-analysis result can subsequently be computed based on that sum, i.e., based on the meta-log-likelihood.
methylSCOPA and META-methylSCOPA
As methylSCOPA and META-methylSCOPA are the extensions for methylation data analysis of SCOPA and META-SCOPA 7 , respectively, installation procedures, command line options, and output columns for methylSCOPA and META-methylSCOPA are largely analogous to those for SCOPA and META-SCOPA, respectively and are detailed in the tutorial provided along the software.
Required file formats
Similarly to SCOPA 7 , methylSCOPA requires phenotype data in GEN/SAMPLE format utilized by the IMPUTE and SNPTESTv.2. The methylation data file format required by the software is described in the tutorial available online http://www.imperial.ac.uk/people/h.draisma/research.html.
Case study

Study populations
To implement our novel methylSCOPA and META-methylSCOPA methods and tools, we performed an MP-EWAS of two correlated glycaemic traits: FI and FG in two independent cohorts, followed by their 
Quality control of the methylation data
Methylation data was quality controlled as follows: we 1) removed duplicate samples, 2) filtered based on methylation detection P-value, 3) performed subset quantile normalization of raw methylation signal intensity values 19 , 4) removed methylation data batch effects using the pipeline CPACOR 20 , 5) detected and removed methylation data outliers as well as samples with gender mismatch, 6) applied white blood cell type composition correction, using "Houseman estimates" 21 
Phenotype definitions, imputation and transformations
We used fasting plasma glucose values (mmol/l) and fasting circulating insulin values (pmol/l) as the main variables of interest in our MP-EWAS. FG was used as such whereas we applied natural log-transformation to FI. We excluded from the analyses non-fasting individuals, pregnant women, diabetic individuals defined as fasting plasma glucose>=7mmol/l; 2-hour post oral glucose tolerance test glucose >=11.1mmol/L, HbA1c>=6.5%; diagnosis of type 1 or type 2 diabetes; or on diabetes treatment [oral and insulin] and individuals on lipid-lowering medication (ATC code "A10"). We then imputed the phenotype data for males and females separately with random forest (MisForest in R). We included use of oral contraceptives for the imputation model for females and additionally for both we included other available indicators of metabolic health, such as blood pressure and metabolomic data. The data for both sexes were combined after imputation. Finally, we regressed out participant sex and smoking status (current/ever/never/unknown), and -in the case of Model 2, see below -BMI, TG, and WHR from the FI and FG values. In fixed-effects meta-analysis of NFBC1966 and NFBC1986 using the functions "escalc" and "rma" in the "R" package 'metafor', the Pearson's product-moment correlation between the resulting FG and FI residuals used for Model 2 analysis was 0.23 (P<0.0001).
MP-EWAS
We fitted two models: Model 1 allows for the detection of effects that might be shared across 'phenotypes of interest' (FG and FI in this case) and measured potential confounders, i.e. confounders were included in the same model. The confounders considered were triglycerides (TG), body mass index (BMI) and
waist/hip ratio (WHR). We regressed out the effect of sex and smoking status (current/ever/never/unknown) from these confounders, similarly as we did for the measurements of FG and FI. Model 2 includes multi-phenotype EWAS of FI/FG corrected for measured potential confounders and allows for the detection of effects that are unique to the phenotypes of interest, i.e. which are not shared with the measured potential confounders. In other words, Model 2 had the measured potential confounders TG, BMI and WHR regressed out from the FG and FI values prior to model fitting.
Mathematically, the two MP-EWAS models fitted were as follows: We meta-analyzed the cohort-specific MP-EWAS results with META-methylSCOPA, mapped genomic locations to CGCh37/hg19, and adopted P<1×10 -7 to denote epigenome-wide significance. From the META-methylSCOPA meta-analysis results, we filtered out associations involving probes that could be cross-reactive, polymorphic, or have been suggested to be excluded from analysis for any other reason by 
Results and discussion
Our MP-EWAS (Figure 1) of 466,342 methylation probes and FG and FI using methylSCOPA and META-methylSCOPA resulted in one epigenome-wide significant signal at cg13708645 (chr12:121,974,3 05;
P_Model1=1.2×10 -8 ; P_Model2=0.48) within KDM2B (Table 1, Figure 1) , and one at suggestive (P<10 -6 ) significance at cg05063096 (chr3:143,689,810; P_Model1=2.0×10 -7 ; P_Model2=2.3×10 -7 ) within C3orf58 (Table 1, Figure 2) .
The locus at KDM2B has the most pronounced association with FI, BMI and WHR in univariate analyses ( Table 2) . It was not significant in Model 2. Model selection for this locus though metaBIC identified BMI and WHR as the most significant phenotype combination (Table 3) , the effect on FI at this locus was driven through its effect on obesity phenotypes. The locus at C3orf58, identified within Model 2 with suggestive significance, showed stronger effect ( Table 1) , when additional phenotypes were considered in Model 1.
The strongest phenotype effects at C3orf58 were on combination of FI and WHR, while the effect on FI in univariate analysis would have not led to the detection of this efpigenetic effect.
The univariate analyses showed that these signals would not have been detected in traditional EWAS for each trait separately, thus, indicating the improved power from the joint analysis of the correlated traits.
We also characterized several established FG/FI or other relevant phenotype-associated EWAS signals through our MP-EWAS approach. A recent large-scale study in 4,808 (discovery) and 11,750 (replication) non-diabetic individuals by Liu et al. reported nine novel differentially methylated sites in whole blood with P<1.27×10 -7 : sites in LETM1, RBM20, IRS2, MAN2A2 genes and 1q25.3 region were associated with FI; sites in FCRL6, SLAMF1, APOBEC3H genes and 15q26.1 region were associated with FG 22 . We show that of the sites associated with FI, 1q25.3 and FAM92B (not replicated in the original study) were also nominally (P<0.05) associated in our study, ( Table 4) . Similarly of the FG-associated sites, BRE (not replicated in the original study) was nominally associated in our study ( Table 4) .
Another study by Zaghlool et al. 23 aimed at elucidating the molecular pathways of 20 previously established CpG sites by using multi-omics data in 359 samples from the multi-ethnic Qatar Metabolomics Study on Diabetes. We observe associations at nominal significance at six of these 20 sites and demonstrate associations within Model 1 at PHGDH, TXNIP, SLC7A11, CPT1A, MYO5C and ABCG1 through the dissection of multi-phenotype effects within our relatively small study sample ( Table 5 ).
Conclusions
We have extended the multi-phenotype analyses to the EWAS framework and implemented this in the publicly available software tools methylSCOPA and METAmethylSCOPA. The application of the method to glycaemic traits demonstrated its enhanced power over single-trait EWAS for correlated phenotypes in large-scale data and the ability to characterize signals that are associated with correlated phenotypes.
Availability and requirements
Project name: methylSCOPA.
Availability: the methylSCOPA and META-methylSCOPA tutorial can be found on "http://www.imperial.ac.uk/people/h.draisma/research.html". The methylSCOPA and META-methylSCOPA software can be found on "http://doi.org/10.5281/zenodo.1137744" and on "https://doi.org/10.5281/zenodo.1286392", respectively.
Operating system(s): Linux.
Programming language: C++ (including files from the ALGLIB project for statistical analysis and the TCLAP project for command line argument parsing).
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Figure 2. Results from the meta-analysis of MP-EWAS for FG and FI from Model 2. A) Manhattan plot,
B) QQ-plot, and C) Regional association plot for the top signal. In the regional association plot, each point represents a CpG passing quality control in the association analysis, plotted with their p-value (on a −log 10 scale) as a function of genomic position (NCBI build GRCh37, UCSC hg 19 assembly). The lead
